Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
Rituximab
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia
1 trial -
Rituximab Paclitaxel Ruxolitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory Diffuse Large B-cell Lymphoma
1 trial -
Roginolisib
United Therapeutics Europe Ltd
Leukemia
1 trial -
Romidepsin
Fondazione Telethon ETS
Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell lymphoma, NOS
1 trial -
Romidepsin
Takeda
Lymphoma, T-Cell, Peripheral
1 trial -
Rozlytrek 200 mg hard capsules
Hoffmann-La Roche
Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
1 trial -
Rucaparib
United Therapeutics Europe Ltd
Cervical Cancer
1 trial -
S-1
United Therapeutics Europe Ltd
Advanced Non-Small Cell Lung Cancer
2 trials -
S-1
United Therapeutics Europe Ltd
Locally Advanced or Metastatic Pancreatic Cancer
1 trial -
S095018
Regeneron UK Limited
Non-small Cell Lung Cancer (NSCLC)
1 trial -
S095031-210
The George Institute
Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation
1 trial -
S095035
Tango Therapeutics
MTAP-deleted Solid Tumors
1 trial -
S1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Gastric Adenocarcinoma
1 trial -
S2023-056-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
S2023-413-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Acute Myeloid Leukemia
1 trial -
S227928
The George Institute
"Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"
1 trial -
SAKK 08/23
Ningbo Cancer Hospital
Metastatic castration-resistant prostate cancer
1 trial -
SAKK 16/18
Ningbo Cancer Hospital
Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)
1 trial -
SAKK 38/19
Ningbo Cancer Hospital
Disseminated large B-cell lymphoma
1 trial -
SAR444881
Regeneron UK Limited
Solid Tumors
1 trial -
SARS-CoV-2 mRNA Vaccine ARCT-021
Arcturus Therapeutics Holdings
Hematopoietic and Lymphatic System Neoplasm
1 trial -
SAVANNAH
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
1 trial -
SAVANNAH/D5084C0007
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer
1 trial -
SCB01A
Biotech Pharmaceutical Co.,
Head and Neck Neoplasms
1 trial -
SCO101-001
Wuhan Createrna Science and Technology Co., Ltd
Metastatic Colorectal Cancer
1 trial -
SDREGN2810
Regeneron UK Limited
Advanced Non-Small Cell Lung Carcinoma
1 trial -
SDX-105
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
1 trial -
SELPERCATINIB, SELPERCATINIB
Wuhan Createrna Science and Technology Co., Ltd
Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.
1 trial -
SELUMETINIB for Metastatic breast cancer
Istituto Gentili S.r.l.
Metastatic breast cancer
1 trial -
SG+I
Xiyuan Hospital of China Academy of Chinese Medical Sciences
TNBC, Triple Negative Breast Cancer
1 trial -
SHR-1210
Hospital Authority, Hong Kong
Renal Cell Carcinoma
1 trial -
SHR-1210
The First People's Hospital of Lianyungang
Resectable Esophageal Squamous Cell Carcinoma
1 trial -
SHR-1701
The First People's Hospital of Lianyungang
Gastric Adenocarcinoma
1 trial -
SHR-1701 Combined With Fluazopalil
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
1 trial -
SHR2554/AZA + Overlapped TBF
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
SI-B001
Sichuan Baili Pharmaceutical Co.,
Non Small Cell Lung Cancer
1 trial -
SIRT Yttrium-90
Chinese University of Hong Kong
Cholangio Carcinoma
1 trial -
SKB103 for injection monotherapy
Sichuan Provincial People's Hospital
Advanced Solid Tumors
1 trial -
SKB264-II-04
Lacuna Pharma Pty Ltd
Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
SMILE
Fondazione Telethon ETS
Subjects at high risk of inflammatory state and mortality from lung cancer, other cancers and all causes
1 trial -
SNDX-5613
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
SNDX-5613-0700
Syndax Pharmaceuticals
Relapsed or Refractory Acute Leukemias
1 trial -
SNS-101 (anti-VISTA)
Regeneron UK Limited
Solid Tumor, Adult
1 trial -
SNS-301
Sensei Biotherapeutics
Squamous Cell Carcinoma of the Head and Neck
1 trial -
SOGUG2020IEC(VEJ)11
Tour Hekla
Muscle-invasive bladder cancer (MIBC)
1 trial -
SOLARIS
The George Institute
advanced stage hepatocellular carcinoma
1 trial -
SOTORASIB
Amgen
Non-small cell lung cancer (NSCLC)
1 trial -
SOTORASIB
Amgen
KRAS p.G12C Mutant Advanced Solid Tumors
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.